Related Experiment Video
Updated: Jan 18, 2026
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Targets of protective immunity and opportunities in hepatitis C virus vaccine development
Seung Bum Park1, Paul Zimmer-Harwood2,3, T Jake Liang4
1Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, USA.
Insights
Developing an effective Hepatitis C virus (HCV) vaccine is crucial for global elimination. Innovative strategies and collaborative efforts are advancing vaccine development despite significant challenges.
Area of Science:
- Hepatology
- Virology
- Vaccinology
Background:
- Hepatitis C virus (HCV) affects nearly 50 million people globally, posing a significant health burden.
- Direct-acting antiviral drugs are effective but cannot prevent reinfection, highlighting the need for a vaccine.
- High HCV genetic diversity and unclear immunity correlates impede vaccine development.
Purpose of the Study:
- To review the current landscape of Hepatitis C virus vaccine development.
- To discuss challenges and innovative strategies in creating an effective HCV vaccine.
- To emphasize the importance of collaboration for global HCV elimination.
Main Methods:
- Review of current scientific literature on HCV vaccine research.
- Analysis of innovative vaccine platforms including subunit, VLP, viral vector, DNA, and RNA vaccines.
- Discussion of controlled human infection models for vaccine testing.
Main Results:
- Several innovative vaccine strategies show promising results in preclinical and early clinical studies.
- Controlled human infection models offer a potential pathway to accelerate vaccine efficacy testing.
- Overcoming challenges requires a concerted effort from diverse stakeholders.
Conclusions:
- An effective HCV vaccine is essential for global HCV elimination.
- Advancements in vaccine technology and research models are crucial.
- Collaboration among researchers, industry, and regulatory bodies is vital for success.
Abstract:
Hepatitis C virus (HCV) remains a serious global health burden that affects nearly 50 million people worldwide. Despite the availability of highly effective direct-acting antiviral drugs, the lack of an effective HCV vaccine hinders control and elimination worldwide, wherein new infections and overall prevalence remain high. HCV vaccine development faces challenges including high genetic diversity of the virus, unclear correlates of protective immunity, and lack of robust in vivo models for vaccine testing. Despite these obstacles, the landscape of HCV vaccine development is rapidly evolving. Innovative strategies, including subunit, virus-like particle, viral vector, DNA and RNA vaccines, show promising results, and controlled human infection models offer a unique, albeit ethically complex, opportunity to accelerate vaccine development. Collaborative efforts among academia, industry, governmental agencies and regulatory bodies are crucial for optimizing vaccine strategies, overcoming current challenges and effecting advances towards global HCV elimination through vaccination.
More Related Videos
Related Concept Videos
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...